Last reviewed · How we verify
NCT04455399: TIVI
Time Efficiency Comparison of Two IntraVitreal Injection Techniques
NA trial testing Intravitreal injection guide (Malosa) in Neovascular Age-related Macular Degeneration in 200 participants. Completed in 9 January 2021.
9 January 2021
Quick facts
| Lead sponsor | Peregrine Eye and Laser Institute |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 200 |
| Start date | 9 November 2020 |
| Primary completion | 9 January 2021 |
| Estimated completion | 9 January 2021 |
| Sites | 1 location across Philippines |
Drugs / interventions tested
- Intravitreal injection guide (Malosa)
- Dual Blade Eyelid Speculum
Conditions studied
- Neovascular Age-related Macular Degeneration — all drugs for Neovascular Age-related Macular Degeneration →
- Diabetic Macular Edema — all drugs for Diabetic Macular Edema →
- Retinal Vein Occlusion With Macular Edema — all drugs for Retinal Vein Occlusion With Macular Edema →
- Uveitic Macular Edema — all drugs for Uveitic Macular Edema →
Sponsor
Peregrine Eye and Laser Institute
Who can join
21 and older, any sex, with Neovascular Age-related Macular Degeneration or Diabetic Macular Edema. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prospective, single-center, randomized, clinical trial (RCT) comparing the time efficiency and safety of a single-use intravitreal injection (IVI) guide versus a traditional technique using a dual blade speculum among patients undergoing IVI for various indications.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Comparison of Two Different Intravitreal Injection Techniques.
Uy HS, Artiaga JCM. · · 2021 · cited 3× · PMID 34135566 · DOI 10.2147/opth.s309501
Verify or expand the search:
- PubMed search for NCT04455399
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neovascular Age-related Macular Degeneration
Currently open trials in the same condition.
- NCT07275840 — A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD · Phase 2 · recruiting
- NCT06847542 — A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD · Phase 3 · recruiting
- NCT07053358 — Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients · EARLY_PHASE1 · recruiting
- NCT06680817 — A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) · recruiting
- NCT06495918 — Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- R · Phase 3 · active not recruiting
Other Peregrine Eye and Laser Institute trials
Trials by the same sponsor.
- NCT04404296 — Pars Plana Vitrectomy With 25-gauge 20000 Cpm, Bevel-tip Cutter · NA · unknown
- NCT04403334 — Postoperative Safety Outcomes of Intraoperative Intracameral Preservative-Free Moxifloxacin Versus Levofloxacin · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04455399 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peregrine Eye and Laser Institute
- Last refreshed: 27 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04455399.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing